Biotech Startups

Corbus Pharmaceuticals is a biopharmaceutical company developing therapies for critical stages of clinical development, with a focus on advancing patient-centered progress in drug development. The company is led by a senior leadership team with expertise in pharmaceutical research, regulatory affairs, and clinical development.

1 investor

CordenPharma is a contract development and manufacturing organization (CDMO) providing high-quality integrated product solutions to pharmaceutical and biotechnology companies across the complete drug lifecycle.

1 investor

Core Diagnostics offers diagnostic laboratory testing with sample collection services, including routine tests and diagnostic monitoring tests scheduled at defined intervals. The company serves individuals seeking medical diagnostic testing.

1 investor

Corealis Pharma is a contract development and manufacturing organization (CDMO) specializing in oral solid dosage formulation and GMP manufacturing for biotech companies developing complex therapies. The company provides services from early-stage formulation through clinical supply, with integrated R&D and manufacturing infrastructure based in Laval, Canada.

1 investor

CoreBone cultivates corals in a closed lab-based aquarium system to produce natural scaffolds for bone and cartilage tissue engineering, offering dental bone grafts as an alternative to bovine and human grafts. Its products serve dental and orthopedic surgical markets, with a cartilage regeneration platform advancing into clinical trials.

1 investor

CoreMedic is a cardiology medical device company developing ChordArt, a minimally invasive system for treating mitral valve regurgitation by replacing mitral chords. Founded as a spin-out in Bern, it now operates from Germany's Tuttlingen medical technology cluster.

1 investor

1 investor

Corion Biotech develops therapeutic solutions for women's health, with a focus on pregnancy-related disorders such as preeclampsia and fetal growth restriction. The company was founded as an academic spin-off from the University of Turin based on over two decades of translational research in obstetrics and gynecology.

1 investor

Corisma develops a fully implanted transcatheter mechanical circulatory support system for advanced heart failure patients, designed to bridge acute and chronic care with improved quality of life. The device eliminates the driveline and uses wireless, catheter-based technology to replace current standard-of-care treatment options.

1 investor

Corium Innovations develops and manufactures drug delivery technologies used in treatments that have reached patients at scale.

1 investor

Cormeo provides an end-to-end software suite for creating, managing, exchanging, and distributing regulated medicinal product information across the life sciences sector, connecting industry, regulatory authorities, healthcare professionals, and patients. It supports regulatory standards such as eCTD, IDMP, ePI, and FHIR to help companies and agencies manage submissions, master data, and approvals.

1 investor

Cornea Sense develops diagnostic technology for detecting systemic and ocular diseases through ocular hydration assessment. The company targets healthcare providers and patients globally to enable earlier disease diagnosis and preventive healthcare interventions.

1 investor

Corrixr Therapeutics is developing targeted genetic medicine for treatment-resistant cancers, with a focus on advancing its CXR101 therapeutic candidate through clinical development and translational research.

1 investor

1 investor

Cortene is developing a patent-protected, peptide-based drug targeting the brain signaling believed to underlie acquired chronic diseases such as Parkinson's, Alzheimer's, dysautonomia, autoimmunity, and ME/CFS. The company operates in biotech, focusing on the root causes of brain-centric chronic conditions.

1 investor

Corventum is a biopharmaceutical company developing therapies that protect the heart from the toxic effects of cancer treatment, allowing patients to continue first-line oncology therapy. Its lead program, CVT-130, is a small molecule for the prevention of anthracycline cardiotoxicity, advancing into the clinic in 2026.

1 investor

Cosmica builds OrganAge™, a blood-based biomarker tool that scores biological aging across nine physiological systems, and an intervention engine that ranks foods, supplements, and activities by how they act on a person's aging-related genes. Aimed at individuals as well as clinics and platform partners, the company applies peer-reviewed aging research to longevity measurement and optimization.

1 investor

COSMIIC develops active implantable medical devices, including its Networked Neuroprosthesis (NNP) modular implant platform that stimulates muscles and records signals to restore function for people with disability and disease. It also provides resources to academic researchers to help translate implantable device concepts into systems tested in first-in-human studies.

1 investor

Cothera Bioscience is a clinical-stage biopharmaceutical company developing small molecule therapies targeting previously undruggable oncology targets through synthetic lethality, protein degradation, and immunotherapy mechanisms. The company's lead candidates are in Phase 2 trials for hematologic malignancies and high-grade gliomas with specific genetic mutations.

1 investor

Countable Labs (formerly Enumerix) develops Countable PCR, a DNA quantification technology that provides absolute target counts at single-molecule resolution as an alternative to qPCR, digital PCR, and NGS. Its genomics tools serve scientists working in biomarker analysis, gene therapeutics, and clinical diagnostics.

1 investor

Couragene develops gene and biologic therapies using novel delivery platforms.

1 investor

CovalX provides mass spectrometry-based analytical services for biotherapeutic development, including epitope mapping, de novo sequencing, and monoclonal antibody characterization. It serves pharmaceutical and biotechnology companies across Europe and the United States, supporting drug discovery and development.

1 investor

Cove GTx develops biodegradable polymeric nanoparticles (PNPs) for non-lipid, non-viral delivery of genetic medicine, aiming to address limitations in delivery efficiency, safety, and manufacturing. The company operates in the genetic medicine and biotechnology field.

1 investor

Covirabio develops diagnostic technology for detecting infectious diseases at the point-of-care/point-of-need. Founded in 2020, the company focuses on infectious disease diagnostics.

1 investor